Scoping Review on Pharmacological Agents for Preventing Liver Cirrhosis Decompensation (Excluding Beta-Blockers) in the Past Decade
Abstract
<h2>Cover Page</h2> <p><strong>Scoping Review on Pharmacological Agents for Preventing Liver Cirrhosis Decompensation (Excluding Beta-Blockers) in the Past Decade</strong></p> <p>Student Name</p> <p>Course Name</p> <p>Instructor Name</p> <p>Institution</p> <p>Date</p> <h2>Evidence Base for Non-Beta-Blocker Pharmacological Prevention of Cirrhosis Decompensation</h2> <p>This scoping review evaluates pharmacological agents, excluding beta-blockers, that have been investigated for preventing decompensation in adults with compensated liver cirrhosis. The review uses a PRISMA-guided screening process and includes 44 studies from PubMed, Ovid Embase, and ClinicalTrials.gov. The evidence focuses on agents such as statins, rifaximin, anticoagulants, antivirals, SGLT-2 inhibitors, GLP-1 receptor agonists, albumin, midodrine, lactulose, UDCA, BCAA, pioglitazone, saroglitazar, resmetirom, spironolactone, norfloxacin, and bulevirtide.</p> <h2>Clinical Outcomes Reported Across Pharmacological Classes</h2> <p>The included studies suggest that several non-beta-blocker agents may delay or reduce major decompensation events, including ascites, hepatic encephalopathy, portal hypertension, variceal bleeding, and liver-related hospitalization. Some agents also showed improvements in MELD scores, Child-Pugh classification, inflammatory markers, transplant-free survival, and hepatic function. However, findings remain variable because the evidence includes randomized controlled trials, observational studies, retrospective cohorts, case reports, and open-label studies.</p> <h2>Promising Therapeutic Strategies for Preventing Decompensation</h2> <p>Statins appear promising because of their vascular, anti-inflammatory, and antifibrotic effects. Evidence suggests that they may reduce portal hypertension, improve endothelial function, lower variceal bleeding risk, and improve survival in selected patients. Rifaximin also shows potential beyond its established use in hepatic encephalopathy by modulating the gut-liver axis, reducing bacterial translocation, lowering systemic inflammation, and improving quality of life. Anticoagulants, including low-molecular-weight heparin and direct oral anticoagulants, may help prevent portal vein thrombosis and support hepatic vascular stability in carefully selected patients.</p> <h2>Strengths and Weaknesses of the Current Evidence</h2> <p>The review benefits from its broad coverage of multiple pharmacological classes and its focus on clinically relevant outcomes such as ascites, hepatic encephalopathy, variceal bleeding, survival, and liver function scores. However, the evidence base remains limited by small sample sizes, short follow-up periods, inconsistent endpoints, heterogeneous study designs, and limited direct comparisons between treatment options. Several promising agents are supported mainly by observational evidence rather than large multicenter randomized controlled trials.</p> <h2>Research Gaps and Priorities for Future Studies</h2> <p>Future research should prioritize long-term randomized controlled trials with standardized outcome measures and broader patient representation. Studies should also examine underexplored agents, combination therapies, and personalized treatment approaches based on cirrhosis etiology, fibrosis stage, MELD score, Child-Pugh class, and comorbidities such as diabetes or renal impairment. More robust safety monitoring is also needed, particularly for agents associated with bleeding risk, myopathy, or hepatic adverse effects.</p> <h2>Clinical Implications for Cirrhosis Management</h2> <p>The findings suggest that selected non-beta-blocker pharmacological agents may eventually contribute to preventive care in compensated cirrhosis. However, routine clinical adoption should remain cautious until stronger evidence confirms long-term safety, efficacy, and cost-effectiveness. Current use should be individualized, monitored carefully, and guided by specialist clinical judgment.</p> <h2>Integrated Conclusions on Pharmacological Prevention of Liver Cirrhosis Decompensation</h2> <p>This scoping review identifies statins, rifaximin, and anticoagulants as particularly promising pharmacological strategies for preventing decompensation in compensated liver cirrhosis. These agents may influence key mechanisms such as portal hypertension, systemic inflammation, bacterial translocation, thrombosis, and fibrosis progression. Although the findings are encouraging, the evidence remains insufficient for universal clinical implementation. Larger multicenter trials with long-term follow-up are required to establish clear recommendations for practice.</p> <h2>References</h2> <p>References retained exactly as presented in the original document.</p>